TriSalus Life Sciences Presents Data For SD-101 Delivered By TriSalus Infusion System For Pancreatic Adenocarcinoma At The Society For Immunotherapy Of Cancer Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
TriSalus Life Sciences (NASDAQ:TLSI) has presented positive safety and feasibility data from a Phase 1 trial of its investigational class C toll-like receptor-9 (TLR9) agonist, SD-101, for pancreatic adenocarcinoma at the Society of Immunotherapy for Cancer (SITC) 2023 Annual Meeting. The data from the PERIO-03 clinical trial indicates that the Pressure-Enabled Drug Delivery (PEDD) method resulted in modulation of the tumor microenvironment. The trial revealed no serious grade 3/4 adverse events related to treatment in three patients who received SD-101 via retrograde venous infusion PEDD at the lowest dose level.
November 03, 2023 | 4:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
TriSalus Life Sciences has presented positive data from a Phase 1 trial of its investigational drug, SD-101, for pancreatic adenocarcinoma. This could potentially boost investor confidence in the company's research and development capabilities.
The positive data from the Phase 1 trial of SD-101 indicates that the drug is safe and feasible for use in patients with pancreatic adenocarcinoma. This could potentially lead to increased investor confidence in TriSalus Life Sciences' research and development capabilities, which could have a positive impact on the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100